International Cardiovascular Research Journal
Volume 16 · Issue 4 · e131422
OPEN PEER REVIEW

LIMA1 Gene Knockout by CRISPR/Cas9 System Using Lentiviruses as an in Vitro Model for Reducing Cholesterol Absorption

Mahdieh Talebzadeh, Vahid Razban, Mahintaj Dara, Hossein Jafari Khamirani, Maryam Ranjbar, Marjan Nourigorji, Farid Torabizadeh, Mehdi Dianatpour

SUBMITTED	REVISED	ACCEPTED
2 Sep 2022	15 Dec 2022	25 Dec 2022

About this report

This open peer review (OPR) report shows the public comments made on this article during peer review, by the reviewers, the associate editor and the editor-in-chief, for every revision round, together with the authors' replies. Comments appear only with the consent of the people who wrote them. Reviewers who chose to sign their report are named; the others are shown as "Referee". Comments are edited for language only, and confidential remarks to the editors are not included.

More about open peer review: brieflands.com/knowledgebase/opr

Contents

1 **Original submission** Referee 1, Associate Editor, Editor-in-Chief 2
2 **Revision 1** Referee 2, Associate Editor, Editor-in-Chief 3
Authors' reply to reviewers 4
Reviewer and editor comments 5

1 Original submission

3 comments · 21 Nov 2022 – 10 Dec 2022

Referee 1 Reviewer

MINOR REVISION 21 Nov 2022

This manuscript is well designed and well written. Some points should be considered:
1- The PCR products of 1,550 bp in length (after deletion of Exon 2) should be sequenced. Please show the sequence diagram as a figure or as supplementary data.

Associate Editor

MINOR REVISION 10 Dec 2022

Needs minor revision.

Editor-in-Chief

MINOR REVISION 10 Dec 2022

Please make the revisions based on the comments.

2

Revision 1

AUTHORS' RESPONSE TO REVIEWERS

Authors' reply to reviewers

The next pages contain the authors' point-by-point reply to the comments of this revision round, as submitted with the revised manuscript. It is published as the authors wrote it.

The authors did not provide a point-by-point response to the reviewers' comments in this round.

2 Revision 1

3 comments · 25 Dec 2022 – 25 Dec 2022

Referee 2 Reviewer — ACCEPT 25 Dec 2022

accept

Associate Editor — ACCEPT 25 Dec 2022

accept

Editor-in-Chief — ACCEPT 25 Dec 2022

Accept